Kitov Pharma Ltd (KTOV)

4.17  +0.09 (+2.21%)

After market: 4.11 -0.06 (-1.44%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

Kitov Pharma Ltd

NASDAQ:KTOV (12/21/2020, 7:00:01 PM)

After market: 4.11 -0.06 (-1.44%)

4.17

+0.09 (+2.21%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorN/A
GICS IndustryN/A
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap65.57M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

KTOV Daily chart

Company Profile

Kitov Pharmaceuticals Holdings Ltd. is a pharmaceutical company which focused on the development of therapeutic candidates. The company's product candidate consists of KIT-302, is formulated for treatment of pain caused by osteoarthritis and hypertension, which can be pre-existing or caused by the treatment for OA. Kitov Pharmaceuticals Holdings Ltd. is based in Jerusalem, Israel.

Company Info

Kitov Pharma Ltd

ONE AZRIELI CENTER ROUND TOWER 132 MENACHEM BEGIN ROAD

TEL AVIV L3 6701101

P: 972-3933-3121

CEO: Isaac Israel

KTOV News

News Image3 years ago - Kitov Pharma Ltd.Purple Biotech to Present at the B. Riley Oncology Investor Conference
News Image3 years ago - Kitov Pharma Ltd.Purple Biotech to Ring the Nasdaq Stock Market Opening Bell
News Image3 years ago - Kitov Pharma Ltd.Kitov Announces Name Change to Purple Biotech Ltd.
News Image3 years ago - Kitov Pharma Ltd.Kitov Pharma to Participate in November Investor Conferences
News Image3 years ago - Kitov Pharma Ltd.Kitov Expands Planned Phase 1/2 Clinical Trial of CM24 in Non-Small Cell Lung Cancer with New Cohort to Evaluate CM24 in Patients with Pancreatic Cancer Conducted with Bristol Myers Squibb

The new cohort will explore the combination of CM24, Opdivo (“nivolumab”) and Abraxane (“albumin-bound paclitaxel; nab-paclitaxel”) in patients with pancreatic cancer

News Image4 years ago - Kitov Pharma Ltd.Kitov Pharma Receives Notice of Allowance for a U.S. Patent Covering its Anti-Cancer Drug Candidate, NT219

KTOV Twits

Here you can normally see the latest stock twits on KTOV, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example